KOTI REYNOLDS: Open Payments
NPI 1285333674 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,738 in 175 payments from 49 companies in 2025. Trend: 2023 $2,247 · 2024 $3,209 · 2025 $4,738
Food & beverage: $3,741Long term medical supply or device loan: $997
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 25 | $1,316 |
| Janssen Biotech, Inc. | 18 | $375 |
| Merck Sharp & Dohme LLC | 9 | $215 |
| ABBVIE INC. | 8 | $208 |
| AstraZeneca Pharmaceuticals LP | 10 | $205 |
| Gilead Sciences, Inc. | 8 | $194 |
| Incyte Corporation | 8 | $187 |
| SOBI, INC | 6 | $155 |
| Astellas Pharma US Inc | 6 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $130 |
Products named: KISQALI, KEYTRUDA, RYBREVANT, Trodelvy, JAKAFI, Vyloy, ENHERTU, Vonjo.
Industry payments across TX — which companies pay providers there.
